Visirna Therapeutics
Chirag Lodaya is a Data Scientist currently employed at Essor since June 2024, focusing on the development and optimization of supply chain components within the CPG e-commerce sector. Previously, Chirag held the position of Data Scientist-II at antuit.ai from October 2021 to June 2024, working on predictive modeling for AI-powered SaaS solutions that enhance decision-making in the digital supply chain. Prior experience includes roles as a Data Scientist and Data Analyst in R&D at Dozee, where statistical and predictive modeling of health data was conducted, as well as a Technical Solutions Engineer Associate at Akamai Technologies, addressing complex issues in Content Delivery Networks. Chirag holds a Post Graduate Program degree in Artificial Intelligence, Machine Learning, and Data Science from the Texas McCombs School of Business and a Bachelor of Engineering in Electronics and Communication Engineering from KLE Technological University.
This person is not in any teams
This person is not in any offices
Visirna Therapeutics
Visirna was founded in 2022 in a strategic partnership with Arrowhead Pharmaceuticals (NASDAQ: ARWR). Based in China, with a global vision, Visirna aims to be a leading player in the research and development of oligonucleotide therapeutics. We currently have three first-in-class late clinical-stage siRNA candidates licensed from Arrowhead Pharmaceuticals for the treatment of cardiovascular and metabolic diseases. We are rapidly advancing our clinical pipelines in an array of trials. Currently, we have one ongoing Phase 3 registration trial in FCS in China, and will soon join multiple MRCT trials for cardiovascular diseases. At the same time, we are also conducting a phase 2 PoC (proof of concept) trial in NASH. Visirna is setting up a 1500 sqm R&D lab in Suzhou BioBAY to strengthen our existing clinical portfolio for cardiovascular and metabolic diseases. Our goal is to develop a comprehensive treatment repertoire that can effectively address the complex nature of these diseases and provide better outcomes for patients.